Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst , Giuseppe Giaccone , Filippo de Marinis , Roy S. Herbst , Giuseppe Giaccone , Filippo de Marinis , Niels Reinmuth , A. Vergnenègre , Carlos H. Barrios , Masahiro Morise , Enriqueta Felip , Zoran Andrić , Sarayut Lucien Geater , Mustafa Özgüroğlu , Wei Zou , Alan Sandler , Ida Enquist , Kimberly M. Komatsubara , Yu Deng , Hiroshi Kuriki , Xiaohui Wen , Mark L. McCleland , Simonetta Mocci , Jacek Jassem , David R. Spigel
2020 New England Journal of Medicine 1,580 citations

Abstract

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of histologic type. (Funded by F. Hoffmann-La Roche/Genentech; IMpower110 ClinicalTrials.gov number, NCT02409342.).

Keywords

AtezolizumabMedicineOncologyInternal medicineLung cancerHazard ratioChemotherapyPopulationImmunohistochemistryPembrolizumabCancerImmunotherapyConfidence interval

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
383
Issue
14
Pages
1328-1339
Citations
1580
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1580
OpenAlex

Cite This

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. (2020). Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. New England Journal of Medicine , 383 (14) , 1328-1339. https://doi.org/10.1056/nejmoa1917346

Identifiers

DOI
10.1056/nejmoa1917346